A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants with Parkinson’s Disease (PD)


Total Award Amount

  • 241251.00
  • Direct Costs

  • 193001.00
  • Sponsor Award Id

  • Contributor

  • Amy Amara   Investigator  
  • Natividad Stover   Principal Investigator